Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Sacituzumab govitecan-hziy |
Synonyms | |
Therapy Description |
Trodelvy (sacituzumab govitecan-hziy) is an antibody-drug conjugate composed of a monoclonal anti-TROP2 antibody linked to the active metabolite of irinotecan (SN-38), which binds to TROP2 positive cancer cells and induces DNA breakage and apoptosis (PMID: 26541586). Trodelvy (sacituzumab govitecan-hziy) is FDA approved for use in patients with metastatic triple-negative breast cancer who received two or more prior therapies, and in patients with locally advanced or metastatic urothelial cancer who received a platinum-containing chemotherapy and a PD-1 orPD-L1 inhibitor (FDA.gov). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Sacituzumab govitecan-hziy | Trodelvy | IMMU-132|Sactizumab|Sacituzumab govitecan | Trodelvy (sacituzumab govitecan-hziy) is an antibody-drug conjugate composed of a monoclonal anti-TROP2 antibody linked to the active metabolite of irinotecan (SN-38), which binds to TROP2 positive cancer cells and induces DNA breakage and apoptosis (PMID: 26541586). Trodelvy (sacituzumab govitecan-hziy) is FDA approved for use in patients with metastatic triple-negative breast cancer who received two or more prior therapies, and in patients with locally advanced or metastatic urothelial cancer who received a platinum-containing chemotherapy and a PD-1 orPD-L1 inhibitor (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04617522 | Phase I | Sacituzumab govitecan-hziy | Study to Determine an Appropriate Starting Dose of Sacituzumab Govitecan-hziy in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment | Recruiting | USA | 0 |
NCT04230109 | Phase II | Sacituzumab govitecan-hziy | Sacituzumab Govitecan In TNBC (NeoSTAR) | Active, not recruiting | USA | 0 |
NCT05089734 | Phase III | Docetaxel Sacituzumab govitecan-hziy | Study of Sacituzumab Govitecan-hziy (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-programmed Death Protein 1 (PD-1)/Programmed Death Ligand 1 (PD-L1) Immunotherapy (EVOKE-01) | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | 12 |
NCT04468061 | Phase II | Sacituzumab govitecan-hziy Pembrolizumab + Sacituzumab govitecan-hziy | Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC | Recruiting | USA | 0 |
NCT03725761 | Phase II | Sacituzumab govitecan-hziy | IMMU-132 in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy | Recruiting | USA | 0 |
NCT04595565 | Phase III | Sacituzumab govitecan-hziy Cisplatin Carboplatin Capecitabine | Sacituzumab Govitecan in Primary HER2-negative Breast Cancer (SASCIA) | Recruiting | ITA | FRA | ESP | DEU | BEL | 2 |
NCT05581589 | Phase II | Sacituzumab govitecan-hziy | Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer | Recruiting | USA | 0 |
NCT05382299 | Phase III | Nab-paclitaxel Carboplatin + Gemcitabine Sacituzumab govitecan-hziy Paclitaxel | Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer (ASCENT-03) | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | 9 |
NCT03547973 | Phase II | Sacituzumab govitecan-hziy | Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer | Recruiting | USA | FRA | 0 |
NCT04527991 | Phase III | Paclitaxel Docetaxel Vinflunine Sacituzumab govitecan-hziy | Study of Sacituzumab Govitecan (IMMU-132) in Metastatic or Locally Advanced Unresectable Urothelial Cancer (TROPiCS-04) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | 19 |
NCT03901339 | Phase III | Eribulin Gemcitabine Vinorelbine Capecitabine Sacituzumab govitecan-hziy | Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | 2 |
NCT04647916 | Phase II | Sacituzumab govitecan-hziy | Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases | Recruiting | USA | 0 |
NCT03964727 | Phase II | Sacituzumab govitecan-hziy | A Study of Sacituzumab Govitecan in Metastatic Solid Tumors (Tropics-03) | Recruiting | USA | FRA | ESP | CAN | BEL | 3 |
NCT04251416 | Phase II | Sacituzumab govitecan-hziy | A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma | Recruiting | USA | 0 |
NCT03995706 | Phase I | Sacituzumab govitecan-hziy | Neuro/Sacituzumab Govitecan/Breast Brain Metastasis/Glioblastoma/Ph 0 | Active, not recruiting | USA | 0 |
NCT05332561 | Phase II | Olaparib Ipatasertib Sacituzumab govitecan-hziy GDC-0077 Pertuzumab/trastuzumab/hyaluronidase-zzxf Atezolizumab | Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE) | Not yet recruiting | DEU | 0 |
NCT02574455 | Phase III | Sacituzumab govitecan-hziy Capecitabine + Eribulin + Gemcitabine + Vinorelbine | ASCENT-Study of Sacituzumab Govitecan in Refractory/Relapsed Triple-Negative Breast Cancer (ASCENT) | Completed | USA | FRA | ESP | DEU | CAN | BEL | 1 |
NCT05226117 | Phase II | Sacituzumab govitecan-hziy | Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer | Recruiting | ITA | 0 |
NCT04559230 | Phase II | Sacituzumab govitecan-hziy | Sacituzumab Govitecan in Recurrent Glioblastoma | Recruiting | USA | 0 |
NCT04448886 | Phase II | Sacituzumab govitecan-hziy Pembrolizumab + Sacituzumab govitecan-hziy | Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC | Recruiting | USA | 0 |